Patents by Inventor Manfred J Stangl

Manfred J Stangl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KYNURENINE: USEFUL BIOMARKER IN ACUTE COVID-19 AND LONG COVID
    Publication number: 20230341417
    Abstract: An in vitro method for the detection of inflammation caused by an acute COVID-19 infection, long COVID and/or PIMS. The level of kynurenine in a body fluid is determined and the value of kynurenine measured in the patient to be diagnosed is compared with the average value obtained from a comparable cohort of persons who do not suffer from said diseases, whereby the value of kynurenine in patients is increased.
    Type: Application
    Filed: April 19, 2023
    Publication date: October 26, 2023
    Applicant: Salion GmbH
    Inventors: Manfred J. STANGL, Dietmar ABENDROTH
  • In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant, a neurodegenerative disorder or a depression
    Patent number: 9983212
    Abstract: An in vitro method for the early detection of a potential inflammation, in particular a rejection of a transplant is disclosed, wherein the level of kynurenine in saliva is determined. The test method can be easily performed and allows the early detection of potential problems.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: May 29, 2018
    Assignee: Salion GmbH
    Inventors: Dietmar Abendroth, Manfred J Stangl, Michael Marzinzig
  • CD34 STEM CELL-RELATED METHODS AND COMPOSITIONS
    Publication number: 20160136207
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated.
    Type: Application
    Filed: May 8, 2015
    Publication date: May 19, 2016
    Applicant: APCETH GMBH & CO. KG
    Inventors: Ralf Huss, Peter J. Nelson, Matthias C. Raggi, Manfred J. Stangl
  • IN VITRO METHOD FOR THE EARLY DETECTION OF A POTENTIAL INFLAMMATION, IN PARTICULAR ASSOCIATED WITH REJECTION OF A TRANSPLANT, A NEURODEGENERATIVE DISORDER OR A DEPRESSION
    Publication number: 20160084843
    Abstract: An in vitro method for the early detection of a potential inflammation, in particular a rejection of a transplant is disclosed, wherein the level of kynurenine in saliva is determined. The test method can be easily performed and allows the early detection of potential problems.
    Type: Application
    Filed: May 2, 2014
    Publication date: March 24, 2016
    Inventors: Dietmar ABENDROTH, Manfred J STANGL, Michael MARZINZIG
  • CD34 STEM CELL-RELATED METHODS AND COMPOSITIONS
    Publication number: 20150238526
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Applicant: APCETH GMBH & CO. KG
    Inventors: Ralf Huss, Peter C. Nelson, Matthias C. Raggi, Manfred J. Stangl
  • CD34 STEM CELL-RELATED METHODS AND COMPOSITIONS
    Publication number: 20150238541
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Inventors: Ralf Huss, Peter C. Nelson, Matthias C. Raggi, Manfred J. Stangl, SR.
  • CD34 Stem Cell-Related Methods and Compositions
    Publication number: 20110268714
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34? stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34? stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.
    Type: Application
    Filed: July 8, 2011
    Publication date: November 3, 2011
    Inventors: Ralf HUSS, Matthias C. Raggi, Manfred J. Stangl, Peter C. Nelson
  • CD34 stem cell-related methods and compositions
    Patent number: 7998472
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34? stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34? stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: August 16, 2011
    Assignee: Apceth GmbH & Co. KG
    Inventors: Ralf Huss, Matthias C Raggi, Manfred J Stangl, Peter C Nelson
  • CD34 Stem cell-related methods and compositions
    Publication number: 20090041735
    Abstract: This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34? stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34? stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.
    Type: Application
    Filed: May 20, 2008
    Publication date: February 12, 2009
    Applicant: Apceth GmbH & Co. KG
    Inventors: Ralf Huss, Matthias C. Raggi, Manfred J. Stangl, Peter C. Nelson